EGFR and non-small cell lung carcinoma: Older patients with EGFR-mutated NSCLC and good performance status, along with fewer than three metastatic sites, have been associated with longer progression-free survival (PFS) and overall survival (OS) when treated with EGFR-TKIs [26].